Qscan-Clinical will include a database of marketed drug label data to assist in comparator study design and data analysis. Clients already using Qscan-ERM with their proprietary post-market safety data will be able to extend their licenses to include the new features and databases. Qscan-Clinical joins the expanding family of Qscan solutions and will be offered in three modes: (a) an application services provider (ASP) mode; (b) integrated with third-party clinical data solutions; and (c) integrated with proprietary pre- and post-market data systems.
Qscan-Clinical analytics can help identify situations that tailor the development of a drug to a specific population or assist in drug re-positioning efforts. Qscan-Clinical will allow companies to monitor drug trials in real time, and begin to explore the types of genomic, proteomic and phenotypic data that are the foundation of personalized medicine. Qscan-Clinical is available now for pilot programs in an ASP mode, and will be available for client site installations by the end of first quarter of 2008.
Colette Saccomanno, director of client research at DrugLogic, said: “To our knowledge, this is the first system that integrates clinical trial data with workflow and analytics that includes all the standard frequency table proportionalities and Bayesian statistics.”